Transderm-V
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.
Zusammensetzung
Arzneiliche Zusammensetzung nicht angegeben.
Nicht arzneiliche Inhaltsstoffe
Light mineral oil, Polyisobutylene 1200000, Polyisobutylene 35000
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | Non précisée | 1 patch | Non précisée |
In Kanada zugelassene Verwendungen
Prevention of symptoms of motion sickness such as nausea and vomiting. To help in the prevention of nausea and vomiting in postoperative patients.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : Warnings: Since drowsiness or visual impairment, disorientation, and confusion may occasionally occur with the use of scopolamine, patients should be cautioned about engaging in activities that require mental alertness, such as driving a motor vehicle or operating dangerous machinery. Potentially alarming idiosyncratic reactions may occur with ordinary therapeutic doses of scopolamine. In patients with a history of possible raised intraocular pressure (pressure pain, blurred vision, glaucomatous halo), TRANSDERM-V should be employed only after ophthalmologic examination excludes glaucoma. TRANSDERM-V should be discontinued if it causes blurring of vision with pressure pain within the eye. Care should be taken after removal of the system as side-effects may persist for up to 24 hours or longer. Due to the presence of aluminum in one of the layers of the system, the patch should be removed before medical scans. Precautions: TRANSDERM-V (scopolamine) should be used with caution in patients with dysuria, eg. due to urinary bladder neck obstruction. Caution should be exercised when administering an antiemetic or antimuscarinic drug to patients suspected of having intestinal obstruction, eg. pyloric stenosis. TRANSDERM-V should be used with caution in the elderly or in individuals with impaired metabolic, liver or kidney functions. In certain cases, especially in the elderly, confusional states and/or visual hallucinations may occur. Should this occur, TRANSDERM-V should be removed at once. If severe symptoms persist, appropriate countermeasures should be taken. In epileptic patients, isolated cases of increased seizure frequency have been reported. Use in Children: Children are particularly susceptible to the side effects of belladonna alkaloids. TRANSDERM-V should not be used in children because it is not known whether the amount of scopolamine released could product serious adverse effects in children. Pregnancy: TRANSDERM-V should be used during pregnancy only if the anticipated benefit justifies the potential risk to the mother and fetus. Lactation: TRANSDERM-V should not be administered to nursing mothers since scopolamine is excreted into breast milk. Consult a health care practitioner prior to use if you are pregnant or breastfeeding (due to lack of sufficient safety evidence for these subpopulations). Drug Interactions: TRANSDERM-V should be employed with caution in patients taking drugs which act on the CNS. This applies particularly to patients under treatment with drugs displaying anticholinergic properties, for example, belladonna alkaloids, antihistamines, antidepressants (tricyclics and MAO inhibitors), phenothiazines, amantadine and quinidine. Any parasympatholytic or sympathomimetic agent, or barbiturate should be administered with caution to persons wearing TRANSDERM-V. Patients should refrain from consuming alcohol while using TRANSDERM-V. Alcohol may interfere with the metabolism of the drug and could thus cause plasma levels to become elevated, which could intensify the side effects.
Originaltext auf Englisch.
Produktdaten
- Inhaber
- Sandoz Canada Inc.
- NPN oder DIN-HM
- 80024336
- Status
- Lizenz nicht aktiv
- Lizenzdatum
- 22. März 2011
- Überarbeitungsdatum
- 28. Mai 2019
- Form
- Timbre transdermique
- Verabreichungsweg
- Transdermique
- Art des Antrags
- Non traditionnelle
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80024336
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.